advertisement
research projects. Researchers at universities and other drug companies also are working toward a diabetes cure, using various strategies. But according to ViaCyte and others, this treatment is the first tested in patients. If the project succeeds, the product could be available in several years for Type 1 diabetes patients and down the road could also treat insulin-using Type 2 diabetics. “This one is potentially the real deal,” said Dr. Tom Donner, director of the diabetes center at Johns Hopkins University School of Medicine. “It’s like making a new pancreas that makes all the hormones” needed to control blood sugar. Donner, who is not involved in the research, said if the device gives patients normal insulin levels, “it’s going to prevent millions of diabetics from getting dangerous complications.” People with Type 1 diabetes no longer produce insulin, the hormone that converts sugar in the blood into energy, because their immune system has killed off the beta cells in thepancreas. Those cells make insulin in response to rising blood sugar levels after a meal. Over years, excess sugar in the bloodstream damages blood vessels and organs. Without effective treatment, diabetics suffer severe complications: blindness, kidney failure, heart disease, amputations, even premature death. On the other hand, too much insulin can cause very low blood sugar, which can kill patients, particularly young children. According to the American Diabetes Association, about 29.1 million Americans have diabetes, including 1.25 million with type 1 diabetes. The number with Type 1, or insulin-dependent, diabetes is growing steadily. Meanwhile, the number with Type 2 diabetes, whose bodies make some insulin but don’t use it efficiently, is increasing exponentially due to the global epidemic of obesity and sedentary lifestyles. Many patients can’t control it well because treatment is exhausting, requiring a strict diet, frequent exercise, multiple daily insulin injections or other
